Payment overview · 2025
General Payments
$915.09
40 reported records · 14 companies
Healthcare provider profile · identity verified
Nabil S. Kamel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · SPRINGFIELD, MO · NPI 1326080276
Verified facts
What the public records show
CMS Open Payments records show Nabil S. Kamel, M.D. received $915.09 in general payments during 2025 across 40 reported records.
Eisai Inc. accounted for 28.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Entresto, Farxiga, Jardiance, Ozempic, Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eisai Inc. | Unresolved — no canonical attribution shown | $261.94 | 28.6% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $142.04 | 15.5% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $139.94 | 15.3% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $72.14 | 7.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.83 | 6.9% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $45.88 | 5.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.51 | 4.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.22 | 3.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.80 | 3.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.87 | 2.3% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.38 | 2.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.49 | 2.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.45 | 1.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.60 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $915.09 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $261.94 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $90.88 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $78.92 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $72.14 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.83 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.73 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $49.06 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $45.88 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.41 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $34.22 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.80 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 38 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
297 | 69 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 813 | 222 |
| Levothyroxine Sodium | Levothyroxine Sodium | 787 | 191 |
| Amlodipine Besylate | Amlodipine Besylate | 773 | 194 |
| Lisinopril | Lisinopril | 676 | 176 |
| Gabapentin | Gabapentin | 499 | 121 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 475 | 140 |
| Omeprazole | Omeprazole | 373 | 98 |
| Losartan Potassium | Losartan Potassium | 333 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 304 | 90 |
| Eliquis | Apixaban | 297 | 69 |
| Furosemide | Furosemide | 283 | 76 |
| Carvedilol | Carvedilol | 280 | 66 |
| Potassium Chloride | Potassium Chloride | 271 | 70 |
| Trazodone Hcl | Trazodone Hcl | 245 | 52 |
| Tramadol Hcl | Tramadol Hcl | 243 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 236 | 71 |
| Metformin Hcl | Metformin Hcl | 234 | 59 |
| Sertraline Hcl | Sertraline Hcl | 229 | 64 |
| Simvastatin | Simvastatin | 227 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 216 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 203 | 58 |
| Donepezil Hcl | Donepezil Hcl | 199 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 167 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 45 |
| Alprazolam | Alprazolam | 160 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 45 |
| Spironolactone | Spironolactone | 152 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 151 | 37 |
| Meloxicam | Meloxicam | 151 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 150 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 148 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 142 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 136 | 46 |
| Allopurinol | Allopurinol | 133 | 41 |
| Lorazepam | Lorazepam | 129 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 124 | 33 |
| Pregabalin | Pregabalin | 120 | 35 |
| Glipizide | Glipizide | 110 | 27 |
| Famotidine | Famotidine | 107 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 107 | 25 |
| Mirtazapine | Mirtazapine | 105 | 22 |
| Alendronate Sodium | Alendronate Sodium | 104 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 100 | 27 |
| Warfarin Sodium | Warfarin Sodium | 100 | 19 |
| Lovastatin | Lovastatin | 95 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 92 | 26 |
| Memantine Hcl | Memantine Hcl | 90 | 25 |
| Montelukast Sodium | Montelukast Sodium | 89 | 20 |
| Finasteride | Finasteride | 81 | 19 |
| Metformin Hcl Er | Metformin Hcl | 81 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 81 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 15 |
| Glimepiride | Glimepiride | 70 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 69 | 14 |
| Ozempic | Semaglutide | 69 | 14 |
| Xarelto | Rivaroxaban | 69 | 17 |
| Clonazepam | Clonazepam | 66 | 21 |
| Myrbetriq | Mirabegron | 66 | 11 |
| Atenolol | Atenolol | 65 | 18 |
| Cephalexin | Cephalexin | 65 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 15 |
| Buspirone Hcl | Buspirone Hcl | 64 | 19 |
| Irbesartan | Irbesartan | 54 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 13 |
| Celecoxib | Celecoxib | 53 | 13 |
| Trulicity | Dulaglutide | 53 | 12 |
| Bupropion Xl | Bupropion Hcl | 52 | 13 |
| Fentanyl | Fentanyl | 51 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 44 |
| Fenofibrate | Fenofibrate | 50 | suppressed |
| Bumetanide | Bumetanide | 46 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | suppressed |
| Jardiance | Empagliflozin | 44 | suppressed |
| Baclofen | Baclofen | 43 | 11 |
| Torsemide | Torsemide | 43 | 11 |
| Temazepam | Temazepam | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 38 | 38 |
| Nystatin | Nystatin | 38 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Prednisone | Prednisone | 35 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Klor-Con M20 | Potassium Chloride | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 29 | 11 |
| Olanzapine | Olanzapine | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Verapamil Sr | Verapamil Hcl | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 14 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 11 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Klor-Con M15 | Potassium Chloride | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $915.09 · 40 records | Eisai Inc. | ABRYSVO, AIRSUPRA, BREZTRI, Belbuca, COMIRNATY, Dexcom G6 Transmitter, ENTRESTO, FARXIGA, FREESTYLE LIBRE, JARDIANCE, KISUNLA, Kerendia, LEQVIO, Leqembi, MOUNJARO, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, REXULTI, Rybelsus, XIFAXAN, YUPELRI, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error